1. Scrip
  2. >>Business
  3. >>Deals

Asia Deal Watch: Shionogi Finds Commercial Partners For Symproic In US, Europe

 
• By Ian Haydock, Anju Ghangurde, Jung Won Shin, and Joseph Haas

Shionogi licenses US commercial rights for OIC drug to BioDelivery and rights in three EU markets to Sandoz. Tessa will test its T-cell therapy with Merck’s Keytruda in cervical cancer.

Osaka Castle in Osaka, Japan
Shionogi is headquartered in Osaka, Japan

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions.

BioDelivery Sciences International Inc. (BDSI) said on April 10 it entered into an exclusive licensing agreement with Shionogi & Co. Ltd. to commercialize Symproic (naldemedine) tablets 0.2mg in the US and Puerto Rico, effective immediately

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business